Clin2
NCT07219407Possibly a fitRecruiting

Long-term safety study of RAP-219 for focal seizures

Focal EpilepsyEpilepsyRefractory Focal EpilepsySeizureFocal SeizureFocal Onset Seizure

Treatments studied

Part of Brain & nervous system clinical trials.

This study tests the long-term safety and effectiveness of RAP-219, an investigative medication for focal epilepsy. It is for people who already completed an earlier study of RAP-219, have a type of epilepsy that doesn't respond to standard medicines, and use a surgically implanted brain device (RNS system) to help manage seizures.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
30 people
Ages
18 years to 70 years
Study type
Interventional

Who can take part

  • You finished the earlier study of RAP-219 and tolerated the treatment well.
  • You have a type of epilepsy called 'refractory focal epilepsy' (seizures that start in one area of the brain and don't respond well to standard medicines).
  • You have a surgically implanted brain device (RNS system) that sends electrical pulses to stop seizures, and your settings are stable.
  • You have a habit of regularly sending data from your RNS system as the study team asks.
  • You are generally healthy other than your epilepsy.
  • If you could become pregnant or get someone pregnant, you must use two effective birth control methods during the study.
  • Your body mass index (BMI) is between 18 and 45.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07563881Recruiting· Phase 3
Testing RAP-219 for Focal Seizure Control in Adults

This study tests whether a new medication called RAP-219 can help adults with focal seizures (seizures that start in one area of the brain) control their seizures better. You would take this medication alongside your current seizure drugs for about 12 weeks.

Palmdale, California
NCT07594119Recruiting· Phase 3
Testing RAP-219 to reduce seizures in focal epilepsy

This study tests a new medication called RAP-219 to see if it can reduce seizure frequency in adults with focal epilepsy (seizures starting in one area of the brain). You'll take the medication alongside your current seizure drugs and track your seizures daily using an app.

Bentonville, Arkansas
NCT05518578Recruiting· Phase 2
Drug trial for hard-to-control focal epilepsy with brain scar

This Phase 2 trial tests SPN-817 in adults whose seizures are still not well controlled despite trying multiple seizure medicines. It targets people with a specific type of brain finding called focal cortical dysplasia and looks at safety/tolerability and seizure outcomes over several weeks.

Jacksonville, Florida
NCT07238868Recruiting· Phase 2
Long-term safety study of CB03-154 for epilepsy

This study is a long-term follow-up for people with epilepsy who already completed a previous trial of the drug CB03-154. It checks if the drug remains safe and effective over more time.

Melbourne, Victoria
NCT06794606Recruiting
Study for drug-resistant focal epilepsy

This trial looks at ways to diagnose and treat focal epilepsy that isn't controlled by medications. It includes patients with or without a visible brain lesion on imaging.

Milan
NCT06425029Recruiting
Music app therapy for hard-to-control epilepsy with RNS

This study is testing a music-based app that you can use at home to help treat seizures. It is for adults with focal epilepsy who already have an RNS device and whose seizures are not controlled by medication.

Worcester, Massachusetts

Hear when a new Focal Epilepsy trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.